Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer

Published:2021-02-25 Issue:7 Volume:11 Page:1672-1687
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Gonzalvez Francois,Vincent Sylvie^ORCID,Baker Theresa E.,Gould Alexandra E.,Li Shuai,Wardwell Scott D.,Nadworny Sara,Ning Yaoyu,Zhang Sen,Huang Wei-Sheng,Hu Yongbo,Li Feng,Greenfield Matthew T.^ORCID,Zech Stephan G.,Das Biplab,Narasimhan Narayana I.,Clackson Tim,Dalgarno David,Shakespeare William C.,Fitzgerald Michael,Chouitar Johara,Griffin Robert J.,Liu Shengwu,Wong Kwok-kin,Zhu Xiaotian,Rivera Victor M.^ORCID

Funder

Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 129 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elucidation of the solution structure of macrocyclic paritaprevir and exploration of its antitumor potential through molecular docking;Journal of Molecular Liquids;2024-09

2. Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer;European Journal of Cancer;2024-09

3. Discovery of flavonoid-containing compound Lupalbigenin as anti-NSCLC cancer agents via suppression of EGFR and ERK1/2 pathway;Bioorganic Chemistry;2024-09

4. Is Autophagy Targeting a Valid Adjuvant Strategy in Conjunction with Tyrosine Kinase Inhibitors?;Cancers;2024-08-28

5. A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations;International Journal of Clinical Oncology;2024-08-27